Meeting
2019 ASCO Annual Meeting
Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).
Authors
Charlene Mantia
Beth Israel Deaconess Medical Center, Boston, MA
Charlene Mantia , Lillian Werner , Sumati Rao , Corey Ritchings , Ahmad A. Tarhini , Michael B. Atkins , David F. McDermott , Meredith M. Regan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9550)
DOI
10.1200/JCO.2019.37.15_suppl.9550
Abstract #
9550
Poster Bd #
121
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).
First Author: Michael B. Atkins
Poster
2014 ASCO Annual Meeting
Association between immune-checkpoint inhibitor induced tumor shrinkage and overall survival in advanced melanoma and NSCLC.
First Author: Yan Feng